FDA Grants Accelerated Approval to GSK's Nelkarmi for ALK-Positive Lung Cancer
11/17/2026
Impact: 75
Healthcare
The FDA granted accelerated approval to GSK’s Nelkarmi for patients with ALK-positive lung cancer, allowing its immediate use in this population. The approval expands GSK’s oncology portfolio; the article reports no financial figures or stock-market impact.
AI summary, not financial advice
Share: